Peptide AOD9604 OXY-AOD (6 mg) OxyPharma

Catalogue entry: Peptide AOD9604 OXY-AOD (6 mg) OxyPharma. Labelled content: 6 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

AOD9604 is a modified peptide based on the C-terminal region of human growth hormone. It is not full-length GH and should not be assumed equivalent to every product labelled HGH Frag 176–191. The exact sequence and modifications determine whether two names identify the same material.

What the research measured

Heffernan and colleagues examined lipid metabolism in mouse models in Endocrinology in 2001. Stier, Vos and Kenley later published a human safety report in 2013. Safety observations in a development programme are different from proof of clinically useful weight loss. Regulatory review of the larger obesity development programme has highlighted the failure to establish a meaningful efficacy advantage.

Sporting claims and limitations

Sporting promotion often presents AOD9604 as a way to separate fat metabolism from other GH effects. That research rationale is not a demonstrated physique outcome. Claims of selective action cannot establish the safety of an unidentified preparation, and limited long-term or formulation-specific data remain relevant. Animal work should not be used to promise fat reduction without trade-offs.

Product identity and documentation

For this item, compare the selected label content with a precise identity specification. A relevant certificate should identify AOD9604, its sequence-related characteristics and chemical form, then link the result to the actual lot. A generic growth-hormone-fragment certificate may describe another material. Product quality, efficacy and authorisation are separate questions, none settled by a total milligram amount.